Invex Therapeutics (ASX:IXC)

Executive Summary

Invex Therapeutics (ASX:IXC) is an Australian biopharmaceutical company pioneering the repurposing of Exenatide, a GLP-1 receptor agonist, under the brand Presendin™ to lower intracranial pressure (ICP) in neurological disorders. The company's lead indication is idiopathic intracranial hypertension (IIH), a condition characterized by elevated ICP and significant morbidity. Additionally, Invex is exploring Presendin for acute stroke and traumatic brain injury (TBI), where elevated ICP is a critical contributor to poor outcomes. By leveraging a known safety profile of Exenatide (approved for diabetes), Invex aims to de-risk development and accelerate regulatory pathways. The company has raised A$12 million to date and is currently in Phase 2 clinical trials. Its strategy capitalizes on the large unmet need in IIH and neurocritical care, with potential to address billion-dollar markets. Invex’s differentiated approach of targeting ICP mechanistically could position it as a first-in-class therapy if successful. However, the company remains early-stage with limited cash runway, relying on trial readouts and potential partnerships to progress.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for Presendin in idiopathic intracranial hypertension (IIH)55% success
• Q4 2026Initiation of Phase 2 trial for Presendin in acute ischemic stroke40% success
• Q2 2026Potential licensing or partnership deal for Presendin in TBI or IIH30% success